SCHEMBL1657138

SCHEMBL1657138

Nc1cc(-c2n[nH]c(=O)c3ccccc23)ccc1N1CCN(Cc2ccccc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 9/20 0.58
ROCK1 Q13464 5/20 0.58
ALDH1A1 P00352 2/20 0.56
GAA P10253 2/20 0.56
KDM4E B2RXH2 1/20 0.56
POLB P06746 1/20 0.56
MAPT P10636 1/20 0.56
ALOX15 P16050 1/20 0.56
HSD17B10 Q99714 1/20 0.56
LMNA P02545 1/20 0.53
TSHR P16473 1/20 0.53
PRMT1 Q99873 1/20 0.48
NCF1 P14598 1/20 0.47
TRPC5 Q9UL62 1/20 0.47
ATM Q13315 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
NAMPT P43490 2/20 0.44
DRD2 P14416 1/20 0.44
DRD4 P21917 1/20 0.44
DRD3 P35462 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1658104 0.93 KDM4E (0.53) ROCK2ROCK1ALDH1A1GAAKDM4E
SCHEMBL1658243 0.90 KDM4E (0.51) ROCK2ROCK1ALDH1A1GAAKDM4E
SCHEMBL1658238 0.87 KDM4E (0.58) ROCK2ROCK1ALDH1A1GAAKDM4E
SCHEMBL1658801 0.87 KDM4E (0.64) ROCK2ROCK1ALDH1A1GAAKDM4E
SCHEMBL1658002 0.86 KDM4E (0.55) ROCK2ROCK1ALDH1A1GAAKDM4E
SCHEMBL12909290 0.85 POLB (0.65) ROCK2ROCK1ALDH1A1GAAKDM4E
SCHEMBL1658774 0.85 ALDH1A1 (0.56) ROCK2ROCK1ALDH1A1GAAKDM4E
SCHEMBL10149829 0.85 ROCK1 (0.60) ROCK2ROCK1ALDH1A1GAAKDM4E
SCHEMBL1658044 0.85 ALDH1A1 (0.53) ROCK2ROCK1ALDH1A1GAAKDM4E
SCHEMBL1658864 0.84 ALDH1A1 (0.61) ROCK2ROCK1ALDH1A1GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098304-A1 Small molecule inhibitors of PARP activity NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-04-28 US claimed
US-20110098304-A1 Small molecule inhibitors of PARP activity NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-04-28 US disclosed
EP-2214667-A2 SMALL MOLECULE INHIBITORS OF PARP ACTIVITY Angion Biomedica Corp. (US) 2010-08-11 EP disclosed
WO-2009054952-A2 SMALL MOLECULE INHIBITORS OF PARP ACTIVITY ANGION BIOMEDICA CORP. (US) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098304-A1 Small molecule inhibitors of PARP activity PARP1, PARP11, PARP2 ROCK2 1184/4885ROCK1 904/4885ALDH1A1 1621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.